Pharmaceutics (Feb 2023)

“Click-to-Clear”: A Strategy to Minimize Radioactivity from the Blood Pool Utilizing Staudinger Ligation

  • Nisarg Soni,
  • Swarbhanu Sarkar,
  • Abhinav Bhise,
  • Yeong Su Ha,
  • Wonchoul Park,
  • A-Ram Yu,
  • Virendra Kumar,
  • Jeong Eun Lim,
  • Young-Ran Yoon,
  • Jeongsoo Yoo

DOI
https://doi.org/10.3390/pharmaceutics15030719
Journal volume & issue
Vol. 15, no. 3
p. 719

Abstract

Read online

The availability of several bioorthogonal reactions that can proceed selectively and efficiently under physiologically relevant conditions has garnered the interest of biochemists and organic chemists alike. Bioorthogonal cleavage reactions represent the latest innovation in click chemistry. Here, we employed the Staudinger ligation reaction to release radioactivity from immunoconjugates, improving target-to-background ratios. In this proof-of-concept study, model systems, including the anti-HER2 antibody trastuzumab, radioisotope I-131, and a newly synthesized bifunctional phosphine, were used. Staudinger ligation occurred when biocompatible N-glycosyl azides reacted with this radiolabeled immunoconjugate, leading to cleavage of the radioactive label from the molecule. We demonstrated this click cleavage in vitro and in vivo. Biodistribution studies in tumor models showed that radioactivity was eliminated from the bloodstream, thereby improving tumor-to-blood ratios. SPECT imaging revealed that tumors could be visualized with enhanced clarity. Our simple approach represents a novel application of bioorthogonal click chemistry in the development of antibody-based theranostics.

Keywords